Crohn’s Disease – Landscape & Forecast – Disease Landscape & Forecast

The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics and targeted oral therapies. The well-established TNF-α inhibitors (e.g., infliximab [Johnson & Johnson Innovative Medicine’s Remicade, biosimilars], adalimumab [AbbVie / Eisai’s Humira, biosimilars]), together with non-TNF biologics (i.e., Takeda’s Entyvio and Johnson & Johnson Innovative Medicine’s Stelara), have transformed the treatment landscape for CD, especially for moderate to severe disease, despite these drugs’ limitations in efficacy and safety. The recent approvals and impending entry of several new therapies offering more-convenient formulations and/or novel mechanisms of action (e.g., AbbVie’s Skyrizi and Rinvoq, Eli Lilly’s mirikizumab, Johnson & Johnson Innovative Medicine’s Tremfya) will further improve treatment and intensify market competition. Reining in some of this sales growth will be the continuing generic erosion of conventional agents and the availability of biosimilar TNF-α inhibitors.

Questions answered

• What do experts say about current targeted therapies (e.g., infliximab, adalimumab, Stelara, Entyvio)? How have biosimilars influenced treatment practices? What factors drive treatment decisions?
• What do KOLs think about recently approved and emerging therapies (e.g., Skyrizi, Rinvoq, mirikizumab, Tremfya) for CD? What impact will the oral therapies have on the CD treatment algorithm?
• Which emerging agents are likely to be most successful in targeting TNF-refractory CD and experiencing uptake in this market?
• How will the market evolve over the next 10 years?

CONTENT HIGHLIGHTS

Geographies: United States, EU5, Japan.

Primary research: 26 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalence of CD by country, segmented by disease activity.

Forecast: 10-year, annualized, drug-level sales and patient share of key CD therapies through 2033, segmented by brands/generics.

Emerging therapies: Phase 3/preregistered: ~4 drugs

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENTS

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.